Noncirrhotic portal hypertension: Another cause of liver disease in HIV patients

Annals of Hepatology

Volumn 8, Issue 4, 2009, Pages 390-395

  Mendizabal, Manuel ^a,b   Craviotto, Soledad ^b   Chen, Terina ^a   Silva, Marcelo O ^b   Rajender Reddy, K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSIDAD AUSTRAL   (Argentina)

Author keywords

Antiretroviral therapy; Didanosine; HIV; Liver; Noncirrhotic portal hypertension

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DIDANOSINE; ANTIRETROVIRUS AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ESOPHAGUS VARICES BLEEDING; FEMALE; HEPATOPORTAL SCLEROSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSPLENISM; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LIVER FUNCTION; LIVER HYPERPLASIA; LIVER NODULAR REGENERATIVE HYPERPLASIA; MALE; NONCIRRHOTIC PORTAL HYPERTENSION; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT DURATION; VIRUS LOAD; CASE REPORT; CHEMICALLY INDUCED DISORDER; MIDDLE AGED;

ADULT; ANTI-RETROVIRAL AGENTS; DIDANOSINE; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; LIVER DISEASES; MALE; MIDDLE AGED;

EID: 77953394322     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31757-0     Document Type: Article

References (30)

1. Molina E, Reddy KR. Noncirrhotic portal hypertension. Clin Liver Dis 2001; 5:769-787.
2. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005; 11: 627-634; discussion 610-621.
3. Tateo M, Sebagh M, Bralet MP, Teicher E, Azoulay D, Mallet V, Pol S, et al. A new indication for liver transplantation: Nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. Liver Transpl 2008; 14: 1194-1198.
4. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44: 7-14.
5. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11: 787-797.
6. Mikkelsen WP, Edmondson HA, Peters RL, Redeker AG, Reynolds TB. Extra- and intrahepatic portal hypertension without cirrhosis (hepatoportal sclerosis). Ann Surg 1965; 162: 602-620.
7. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fu-hrer J, Satten GA, Aschman DJ, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
8. Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, Heripret L, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799-805.
9. Maida I, Nunez M, Rios MJ, Martin-Carbonero L, Sotgiu G, Toro C, Rivas P, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42: 177-182.
10. Arey B, Markov M, Ravi J, Prevette E, Batts K, Nadir A. Nodular regenerative hyperplasia of liver as a consequence of ART. AIDS 2007; 21: 1066-1068.
11. Garvey LJ, Thomson EC, Lloyd J, Cooke GS, Goldin RD, Main J. Response to Mallet, et al. 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'. AIDS 2007; 21: 1494-1495.
12. Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, Pol S. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21: 187-192.
13. Podevin P, Spiridon G, Terris B, Chauvelot-Moachon L, Gui-llevin L, Chaussade S, Sogni P, et al. Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient. AIDS 2006; 20: 313-315.
14. Sandrine PF, Sylvie A, Andre E, Abdoulaye D, Bernard L, Andre C. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? AIDS 2007; 21: 1498-1499.
15. Schiano TD, Kotler DP, Ferran E, Fiel ML. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102: 2536-2540.
16. Saifee S, Joelson D, Braude J, Shrestha R, Johnson M, Sellers M, Galambos MR, et al. Noncirrhotic portal hyperten- sion in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008; 6: 1167-1169.
17. Okudaira M, Ohbu M, Okuda K. Idiopathic portal hypertension and its pathology. Semin Liver Dis 2002; 22: 59-72.
18. Sarin SK, Kumar A. Noncirrhotic portal hypertension. Clin Liver Dis 2006; 10: 627-651.
19. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44: S132-S139.
20. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Leder-man MM, Maartens G, Wakeford C, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191: 825-829.
21. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mo-croft A, Cruceta A, Marcos MA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
22. Macias J, Castellano V, Merchante N, Palacios RB, Mira JA, Saez C, Garcia-Garcia JA, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18: 767-774.
23. Maida I, Garcia-Gasco P, Sotgiu G, Rios MJ, Vispo ME, Mar-tin-Carbonero L, Barreiro P, et al. Antiretroviral-associa-ted portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13: 103-107.
24. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, Bernuau J, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosi-ne therapy. J Intern Med 1994; 235: 367-371.
25. Praprotnik S, Hocevar A, Ferlan-Marolt V, Tomsk M. Aza-thioprine induced hepatic veno-occlusive disease in systemic lupus erythematosus. Lupus 2005; 14: 493-494.
26. Klein SK, Slim EJ, de Kruif MD, Keller TT, ten Cate H, van Gorp EC, Brandjes DP. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med 2005; 63: 129-136.
27. Veazey RS, Lackner AA. Getting to the guts of HIV pathogenesis. J Exp Med 2004; 200: 697-700.
28. Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost 2003; 9: 325-331.
29. Bureau C, Pagan JC, Layrargues GP, Metivier S, Bellot P, Perreault P, Otal P, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugu-lar intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27: 742-747.
30. Devarbhavi H, Abraham S, Kamath PS. Significance of nodular regenerative hyperplasia occurring de novo following liver transplantation. Liver Transpl 2007; 13: 1552-1556.